Drug overdose is the leading cause of unintentional death in the United States, and opioids are the most common cause of fatal overdoses. With the ability to stop an overdose in its tracks, naloxone is a life-saving medication. Learn about the laws surrounding its use, the available naloxone products, and the logistics of dispensing take-home formulations.
Following the completion of this knowledge-based activity, pharmacists and pharmacy technicians will be able to:
- Describe validated tools and practice-based methods to assess the risk for opioid-induced respiratory depression.
- Identify models for overdose education and naloxone distribution that are applicable to various practice settings
- Describe strategies to overcome some of the barriers to implementing overdose education and naloxone distribution.
- Summarize and demonstrate essential patient/caregiver overdose education elements for community health care settings.
- Explain evolving state laws regarding options for pharmacists to prescribe and/or dispense naloxone under collaborative practice agreements, protocols and standing orders.
Activity type: Knowledge-based
Target Audience: Pharmacists and Pharmacy Technicians
Learning Level: 2
The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The following archived webinar is approved for 1 contact hour of CPE credit (0.1 CEUs). The ACPE Universal Activity Number for this activity is 0202-0000-20-118-H08-P/T.
To obtain credit for completing Naloxone: Understanding Its Role and Use in the Community participants will need to watch the archived webinar, complete the assessment with a grade of 70% or better, complete the evaluation questions, and then CLAIM credit. Participants need to have a valid pharmacist.com username and password to claim credit. After credit has been claimed, please visit CPE monitor for your transcript.
APhA continuing pharmacy education policy provides you with two opportunities to successfully complete this continuing pharmacy education assessment. Please note that you will not be permitted to submit the assessment a third time. The current policy of the APhA Education Department is not to release the correct answers to any of our CPE tests. This policy is intended to maintain the integrity of the CPE activity and the assessment.Initial release date: March 2, 2020
Expiration date: February 1, 2023 - No credit granted after this date
Development and Support
Naloxone: Understanding Its Role and Use in the Community is a continuing education activity for pharmacists and pharmacy technicians developed by the American Pharmacists Association. © 2020 American Pharmacists Association.
This program is supported by an independent educational grant from Walmart, Inc.
Anita N. Jacobson, PharmD and APhA’s editorial staff declare no conflicts of interest or financial interests in any product or service mentioned in this activity, including grants, employment, gifts, stock holdings, and honoraria. For a complete list of APhA staff disclosures, visit the APhA website at www.pharmacist.com/apha-disclosures.
Conflicts of interest have been resolved through content review by Helen Sairany, BA, PharmD, MBA, BCACP, Director of Content Development & Partnership at the American Pharmacists Association.
This learning activity is a component of the APhA Pain Management Forum.
Computer and internet access are required to complete this activity. Please visit our website to view the Technology System Requirements in order to have a positive learning experience.
|Activity Number||Credit Amount||Accreditation Period|
|ACPE# 0202-0000-20-118-H08-P||0.1 CEUs||February 01, 2020 - February 01, 2023|
|ACPE# 0202-0000-20-118-H08-T||0.1 CEUs||February 01, 2020 - February 01, 2023|